Identification

Name
Labetalol
Accession Number
DB00598  (APRD01062)
Type
Small Molecule
Groups
Approved
Description

Blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. [PubChem]

Structure
Thumb
Synonyms
  • 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
  • 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
  • Labetalol
  • Labetalolum
  • Labetolol
Product Ingredients
IngredientUNIICASInChI Key
Labetalol Hydrochloride1GEV3BAW9J32780-64-6WQVZLXWQESQGIF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol HydrochlorideTablet300 mg/1OralCounty Line Pharamceuticals2014-12-01Not applicableUs
Labetalol HydrochlorideTablet100 mg/1OralRemedy Repack2016-11-30Not applicableUs
Labetalol HydrochlorideTablet100 mg/1OralCounty Line Pharamceuticals2014-12-01Not applicableUs43199 0037 01 nlmimage10 4c44a635
Labetalol HydrochlorideTablet100 mg/1OralNucare Pharmaceuticals, Inc.2014-12-01Not applicableUs
Labetalol HydrochlorideTablet200 mg/1OralCounty Line Pharamceuticals2014-12-01Not applicableUs43199 0038 01 nlmimage10 5644ab15
Labetalol HydrochlorideTablet200 mg/1OralA S Medication Solutions2014-12-012017-06-20Us
Labetalol Hydrochloride InjectionSolution5 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Labetalol Hydrochloride Injection USPSolution5 mgIntravenousPfizer2015-06-02Not applicableCanada
Labetalol Hydrochloride Injection USPLiquid5 mgIntravenousSandoz Canada Incorporated1998-03-17Not applicableCanada
Labetalol Hydrochloride Injection, USPSolution5 mgIntravenousMylan Pharmaceuticals2012-08-29Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-labetalol TabletsTablet100 mgOralApotex Corporation2001-03-16Not applicableCanada
Apo-labetalol TabletsTablet200 mgOralApotex Corporation2001-06-01Not applicableCanada
LabetalolInjection, solution5 mg/mLIntravenousSagent Pharmaceuticals2010-02-172017-06-20Us
LabetalolTablet, film coated300 mg/1OralSun Pharmaceutical Industries Limited1999-07-29Not applicableUs
LabetalolTablet, film coated100 mg/1OralSun Pharmaceutical Industries Limited1999-07-29Not applicableUs
LabetalolTablet, film coated200 mg/1OralSun Pharmaceutical Industries Limited1999-07-29Not applicableUs
Labetalol HClTablet, film coated300 mg/1OralCardinal Health1998-08-042017-04-27Us
Labetalol HCLTablet, film coated100 mg/1OralRemedy Repack2016-02-23Not applicableUs
Labetalol HClTablet, film coated200 mg/1OralRemedy Repack2013-10-292016-10-13Us00185 0117 01 nlmimage10 d520eaa7
Labetalol HClTablet, film coated200 mg/1OralAmerincan Health Packaging2015-06-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol HClInjection, solution5 mg/mLIntravenousCantrell Drug Company2012-02-23Not applicableUs
Labetalol HydrochlorideTablet, film coated300 mg/1OralMethod Pharmaceuticals2017-11-15Not applicableUs
Labetalol HydrochlorideTablet, film coated100 mg/1OralMethod Pharmaceuticals2017-11-15Not applicableUs
Labetalol HydrochlorideTablet, film coated200 mg/1OralMethod Pharmaceuticals2017-11-15Not applicableUs
International/Other Brands
Albetol (Leiras) / Latol (Standard) / Normadate (GlaxoSmithKline) / Normodyne (Schering)
Categories
UNII
R5H8897N95
CAS number
36894-69-6
Weight
Average: 328.4055
Monoisotopic: 328.178692644
Chemical Formula
C19H24N2O3
InChI Key
SGUAFYQXFOLMHL-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
IUPAC Name
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
SMILES
CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1

Pharmacology

Indication

For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.

Structured Indications
Pharmacodynamics

Labetalol is an selective alpha-1 and non-selective beta adrenergic blocker used to treat high blood pressure. It works by blocking these adrenergic receptors, which slows sinus heart rate, decreases peripheral vascular resistance, and decreases cardiac output. Labetalol has two asymmetric centers and therefore, exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, makes up 25% of racemic labetalol.

Mechanism of action

Labetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
Absorption

Completely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.

Volume of distribution
Not Available
Protein binding

50%

Metabolism

Primarily hepatic, undergoes significant first pass metabolism

Route of elimination

These metabolites are present in plasma and are excreted in the urine, and via the bile, into the feces.

Half life

6-8 hours

Clearance
Not Available
Toxicity

LD50 = 66 mg/kg (Rat, IV). Side effects or adverse reactions include dizziness when standing up, very low blood pressure, severely slow heartbeat, weakness, diminished sexual function, fatigue

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Labetalol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Labetalol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Labetalol.Experimental
AbirateroneThe serum concentration of Labetalol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Labetalol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Labetalol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Labetalol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Labetalol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Labetalol.Approved
AcetohexamideLabetalol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.Approved
AcetyldigitoxinLabetalol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinLabetalol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Labetalol.Approved
AdrafinilLabetalol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Labetalol.Experimental, Investigational
AlaproclateThe serum concentration of Labetalol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Labetalol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Labetalol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Labetalol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Labetalol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Labetalol.Experimental
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Labetalol.Approved
AmbrisentanLabetalol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronLabetalol may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineLabetalol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Labetalol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Labetalol.Approved, Investigational
AmitrazLabetalol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Labetalol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Labetalol.Approved, Illicit
AmodiaquineThe metabolism of Labetalol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Labetalol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Labetalol.Approved, Investigational
AmrinoneLabetalol may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Labetalol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Labetalol.Investigational
AnisodamineLabetalol may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Labetalol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Labetalol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Labetalol.Approved, Investigational
ArbutamineLabetalol may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Arecoline.Experimental
ArformoterolLabetalol may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Labetalol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Labetalol.Approved, Investigational
ArtemetherThe metabolism of Labetalol can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Labetalol.Approved
AvanafilAvanafil may increase the hypotensive activities of Labetalol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Labetalol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Labetalol.Approved
AzelnidipineLabetalol may increase the hypotensive activities of Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.Approved
AzimilideLabetalol may increase the hypotensive activities of Azimilide.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Labetalol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Labetalol.Experimental
BarbitalBarbital may increase the hypotensive activities of Labetalol.Illicit
BarnidipineLabetalol may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Labetalol.Approved, Investigational
BencyclaneLabetalol may increase the hypotensive activities of Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Labetalol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Labetalol.Approved
BenidipineLabetalol may increase the hypotensive activities of Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Labetalol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Labetalol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Labetalol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Labetalol.Approved
BepridilLabetalol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantLabetalol may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Labetalol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Labetalol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Labetalol.Experimental
BimatoprostLabetalol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BitolterolLabetalol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Labetalol.Investigational
BopindololBopindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Labetalol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Labetalol.Approved, Investigational
BQ-123Labetalol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Labetalol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Labetalol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Labetalol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Labetalol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Labetalol.Investigational
BucindololLabetalol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Labetalol.Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Labetalol.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Labetalol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.Approved
BunazosinLabetalol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BupropionThe metabolism of Labetalol can be decreased when combined with Bupropion.Approved
CabergolineLabetalol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Labetalol.Experimental
CafedrineLabetalol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantLabetalol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.Approved
CandesartanLabetalol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Labetalol is combined with Candesartan cilexetil.Approved
CandoxatrilLabetalol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Labetalol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Labetalol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Labetalol.Approved
CarboxyamidotriazoleLabetalol may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CarbutamideLabetalol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineLabetalol may increase the hypotensive activities of Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Labetalol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Labetalol.Approved
CarvedilolLabetalol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Labetalol.Experimental
CelecoxibThe metabolism of Labetalol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
CeritinibLabetalol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Labetalol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Labetalol.Experimental
ChlorpromazineThe metabolism of Labetalol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideLabetalol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Labetalol.Approved
CholecalciferolThe metabolism of Labetalol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Labetalol.Approved
CicletanineLabetalol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Cilazapril.Approved
CilnidipineLabetalol may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Labetalol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Labetalol can be decreased when combined with Cinacalcet.Approved
CinnarizineLabetalol may increase the hypotensive activities of Cinnarizine.Approved, Investigational
CirazolineLabetalol may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe metabolism of Labetalol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Labetalol can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Labetalol is combined with Clevidipine.Approved
ClobazamThe metabolism of Labetalol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Labetalol.Approved, Investigational
ClomipramineThe metabolism of Labetalol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Labetalol.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
ClotrimazoleThe metabolism of Labetalol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Labetalol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Labetalol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Labetalol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Labetalol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Labetalol.Vet Approved
CrizotinibLabetalol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineLabetalol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Labetalol.Investigational
CyclopenthiazideLabetalol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideLabetalol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinLabetalol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Labetalol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Labetalol.Investigational
DarifenacinThe metabolism of Labetalol can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineLabetalol may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Labetalol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Labetalol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Labetalol.Approved
DelaprilLabetalol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Labetalol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Labetalol.Approved
DeserpidineLabetalol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Labetalol.Approved
DesipramineThe metabolism of Labetalol can be decreased when combined with Desipramine.Approved
DeslanosideLabetalol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.Approved
DetomidineLabetalol may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Labetalol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Labetalol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Diclofenamide.Approved
diethylnorspermineLabetalol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Labetalol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Labetalol.Approved
DigitoxinLabetalol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinDigoxin may increase the bradycardic activities of Labetalol.Approved
Digoxin Immune Fab (Ovine)Labetalol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Labetalol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Labetalol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Labetalol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Labetalol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Labetalol.Approved
DistigmineDistigmine may increase the bradycardic activities of Labetalol.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Labetalol.Approved
DopamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.Approved
DopexamineLabetalol may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamideLabetalol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Labetalol can be decreased when combined with Dosulepin.Approved
DotarizineLabetalol may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinLabetalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Labetalol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Labetalol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Labetalol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
DuloxetineLabetalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Labetalol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Labetalol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Labetalol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Labetalol.Approved
EfonidipineLabetalol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Labetalol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Labetalol.Approved, Vet Approved
EnalaprilatLabetalol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Labetalol.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
EperisoneLabetalol may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Epibatidine.Experimental
EpinastineLabetalol may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Labetalol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Labetalol is combined with Eplerenone.Approved
EpoprostenolLabetalol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Labetalol is combined with Eprosartan.Approved
Ergoloid mesylateLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineLabetalol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Labetalol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Labetalol.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Labetalol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
EtoperidoneThe serum concentration of Labetalol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Labetalol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Labetalol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Labetalol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Labetalol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Labetalol.Approved
FendilineLabetalol may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamLabetalol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Labetalol.Approved
FenoterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Labetalol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Labetalol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Labetalol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Labetalol.Experimental
Ferulic acidLabetalol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Labetalol.Approved, Investigational
FingolimodLabetalol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Labetalol.Approved, Withdrawn
FlunarizineLabetalol may increase the hypotensive activities of Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Labetalol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Labetalol.Experimental
FluoxetineThe metabolism of Labetalol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Labetalol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
FluvoxamineThe metabolism of Labetalol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolLabetalol may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Labetalol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Labetalol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.Approved, Vet Approved
GabapentinLabetalol may increase the hypotensive activities of Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Labetalol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Labetalol.Approved
GallopamilLabetalol may increase the hypotensive activities of Gallopamil.Investigational
GitoformateLabetalol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideLabetalol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideLabetalol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLabetalol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLabetalol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneLabetalol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideLabetalol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideLabetalol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Labetalol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Labetalol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Labetalol.Approved
GuanazodineLabetalol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLabetalol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
GuanoclorLabetalol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLabetalol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLabetalol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Labetalol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Labetalol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Labetalol.Experimental
HexamethoniumLabetalol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Labetalol.Approved
HexoprenalineLabetalol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineHigenamine may decrease the antihypertensive activities of Labetalol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Labetalol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Labetalol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideLabetalol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe metabolism of Labetalol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Labetalol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Labetalol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Labetalol.Approved
IloprostIloprost may increase the hypotensive activities of Labetalol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Labetalol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Labetalol.Experimental
ImipramineThe metabolism of Labetalol can be decreased when combined with Imipramine.Approved
IndalpineThe serum concentration of Labetalol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Labetalol.Withdrawn
IndinavirThe metabolism of Labetalol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Labetalol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Labetalol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Labetalol.Withdrawn
IndoraminLabetalol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanLabetalol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkLabetalol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Labetalol.Approved, Investigational
IpidacrineIpidacrine may increase the bradycardic activities of Labetalol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Labetalol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Labetalol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Labetalol is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Labetalol.Approved
IsoetarineLabetalol may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Labetalol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Labetalol.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Labetalol can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Labetalol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Labetalol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Labetalol.Approved
IvabradineLabetalol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Labetalol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Labetalol.Investigational
KetoconazoleThe metabolism of Labetalol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Labetalol.Approved
LacidipineLabetalol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideLabetalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineLabetalol may increase the hypotensive activities of Lamotrigine.Approved, Investigational
Lanatoside CLabetalol may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Labetalol.Investigational
LanreotideLabetalol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLabetalol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Labetalol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Labetalol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Labetalol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Labetalol.Approved, Investigational
LevodopaLabetalol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Labetalol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Labetalol.Approved, Vet Approved
LidoflazineLabetalol may increase the hypotensive activities of Lidoflazine.Experimental
LinezolidLinezolid may increase the hypertensive activities of Labetalol.Approved, Investigational
LinsidomineLabetalol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Labetalol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Labetalol.Experimental
LopinavirThe metabolism of Labetalol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Labetalol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Labetalol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Labetalol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
LucinactantLabetalol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumefantrineThe metabolism of Labetalol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational
MacitentanLabetalol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Labetalol.Approved
Magnesium SulfateLabetalol may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
MalathionMalathion may increase the bradycardic activities of Labetalol.Approved, Investigational
ManidipineLabetalol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Labetalol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Labetalol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
MedetomidineLabetalol may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Labetalol.Approved
MefenorexThe risk or severity of adverse effects can be increased when Labetalol is combined with Mefenorex.Experimental
MefloquineMefloquine may increase the bradycardic activities of Labetalol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Labetalol.Approved, Investigational
MephentermineLabetalol may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Labetalol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Labetalol.Approved, Investigational
MetahexamideLabetalol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Labetalol.Investigational, Withdrawn
MetaraminolLabetalol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Methacholine.Approved
MethadoneThe metabolism of Labetalol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Labetalol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Labetalol.Approved
MethoserpidineLabetalol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Labetalol can be decreased when combined with Methotrimeprazine.Approved
MethoxamineLabetalol may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineLabetalol may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Labetalol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Labetalol.Approved, Investigational
MethylergometrineLabetalol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Labetalol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Labetalol.Approved
MetildigoxinLabetalol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Labetalol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Labetalol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Labetalol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Labetalol.Approved, Investigational
MetyrosineLabetalol may increase the hypotensive activities of Metyrosine.Approved
MibefradilLabetalol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineLabetalol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Labetalol can be decreased when combined with Midostaurin.Approved
MilnacipranThe serum concentration of Labetalol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Labetalol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Labetalol.Approved
MirabegronThe metabolism of Labetalol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Labetalol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Labetalol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Labetalol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Labetalol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Labetalol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Labetalol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
MuzolimineLabetalol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Labetalol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Labetalol.Approved
NabiloneNabilone may increase the tachycardic activities of Labetalol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Labetalol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Labetalol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Labetalol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Labetalol.Approved
NaftopidilLabetalol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
NefazodoneThe serum concentration of Labetalol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Labetalol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Labetalol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Labetalol is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Labetalol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Labetalol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Labetalol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Labetalol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Labetalol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Labetalol.Approved
NiguldipineLabetalol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Labetalol can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineLabetalol may increase the hypotensive activities of Niludipine.Experimental
NilvadipineLabetalol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideLabetalol may increase the hypotensive activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Labetalol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Labetalol.Approved
NitrendipineLabetalol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Labetalol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Labetalol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Labetalol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Labetalol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
NorfenefrineLabetalol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinThe risk or severity of adverse effects can be increased when Labetalol is combined with Nylidrin.Approved
ObinutuzumabLabetalol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Labetalol.Withdrawn
OctopamineLabetalol may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the bradycardic activities of Labetalol.Approved, Investigational
OleandrinLabetalol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Labetalol.Approved, Investigational
OlodaterolLabetalol may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Labetalol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Labetalol.Approved
OmapatrilatLabetalol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Labetalol.Vet Approved
OtiloniumLabetalol may increase the hypotensive activities of Otilonium.Experimental, Investigational
OuabainLabetalol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Labetalol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
OxyfedrineLabetalol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Labetalol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
PanobinostatThe serum concentration of Labetalol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Labetalol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Labetalol.Approved
PargylinePargyline may increase the hypotensive activities of Labetalol.Approved
ParoxetineThe metabolism of Labetalol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Labetalol.Investigational
PasireotideLabetalol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Labetalol.Approved, Vet Approved
PentoliniumLabetalol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Labetalol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Labetalol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineLabetalol may increase the hypotensive activities of Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Labetalol.Approved
PeruvosideLabetalol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Labetalol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Labetalol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phenmetrazine.Approved, Illicit
PhenobarbitalPhenobarbital may increase the hypotensive activities of Labetalol.Approved
PhenoxybenzamineLabetalol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Labetalol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.Approved, Illicit
PhentolamineLabetalol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
PhenylephrineLabetalol may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Labetalol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Labetalol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Labetalol.Withdrawn
PinaveriumLabetalol may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Labetalol.Approved, Investigational
PirbuterolLabetalol may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Labetalol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Labetalol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Labetalol.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Labetalol.Experimental
PolythiazideLabetalol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaLabetalol may increase the bradycardic activities of Poractant alfa.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Labetalol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Labetalol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Labetalol.Experimental, Investigational
PrazosinLabetalol may increase the orthostatic hypotensive activities of Prazosin.Approved
PregabalinLabetalol may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Prenalterol.Experimental
PrenylamineLabetalol may increase the hypotensive activities of Prenylamine.Withdrawn
PrimaquineThe metabolism of Labetalol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Labetalol.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Labetalol is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Labetalol.Experimental
PromazineThe metabolism of Labetalol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Labetalol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PropafenoneThe serum concentration of Labetalol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Labetalol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Labetalol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Labetalol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Labetalol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Labetalol.Experimental
ProscillaridinLabetalol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Labetalol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Labetalol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Labetalol is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Labetalol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Labetalol.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Racepinephrine.Approved
RactopamineLabetalol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Labetalol.Approved
RanolazineThe metabolism of Labetalol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Labetalol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Labetalol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Labetalol.Approved
RemikirenRemikiren may increase the hypotensive activities of Labetalol.Approved
ReproterolLabetalol may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineLabetalol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Labetalol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Labetalol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Labetalol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Labetalol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Labetalol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Labetalol.Investigational
RimiterolLabetalol may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Labetalol is combined with Riociguat.Approved
RisedronateLabetalol may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneLabetalol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronLabetalol may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Labetalol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabLabetalol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Labetalol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Labetalol.Investigational, Withdrawn
RolapitantThe metabolism of Labetalol can be decreased when combined with Rolapitant.Approved
RomifidineLabetalol may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Labetalol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Labetalol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Labetalol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Labetalol.Approved
SafrazineSafrazine may increase the hypotensive activities of Labetalol.Withdrawn
SalbutamolLabetalol may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Labetalol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
SalmeterolLabetalol may decrease the vasoconstricting activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Labetalol.Approved
SaprisartanLabetalol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Labetalol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Labetalol.Approved, Investigational, Vet Approved
SelexipagLabetalol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Labetalol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Labetalol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Labetalol.Investigational
SertralineThe metabolism of Labetalol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Labetalol.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Labetalol.Approved, Investigational
SilodosinLabetalol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanLabetalol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Labetalol.Approved
SolabegronLabetalol may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Labetalol.Approved
SpiraprilLabetalol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Labetalol.Investigational
StiripentolThe metabolism of Labetalol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.Approved, Investigational
SufentanilLabetalol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Labetalol.Approved
SulindacSulindac may decrease the antihypertensive activities of Labetalol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Labetalol.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Labetalol.Investigational, Withdrawn
TadalafilTadalafil may increase the hypotensive activities of Labetalol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Labetalol.Investigational
TamsulosinLabetalol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Labetalol.Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Labetalol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Labetalol is combined with Telmisartan.Approved, Investigational
TemocaprilLabetalol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Labetalol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Labetalol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Labetalol.Vet Approved
TerazosinLabetalol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Labetalol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Labetalol.Approved
TerlipressinLabetalol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineLabetalol may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
TetrahydropalmatineLabetalol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Labetalol.Approved, Investigational, Withdrawn
TheodrenalineLabetalol may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Labetalol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Labetalol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Labetalol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Labetalol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Labetalol.Approved
TiboloneLabetalol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Labetalol can be decreased when combined with Ticlopidine.Approved
TicrynafenLabetalol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Labetalol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Labetalol.Investigational
TipranavirThe metabolism of Labetalol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Labetalol.Approved, Investigational
TolazamideLabetalol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineLabetalol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideLabetalol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Labetalol.Approved, Withdrawn
Tolfenamic AcidLabetalol may increase the hypotensive activities of Tolfenamic Acid.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Labetalol.Approved
TolonidineLabetalol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Labetalol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Labetalol.Approved
TramazolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tramazoline.Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Labetalol.Approved
TranilastLabetalol may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Labetalol.Experimental
TranylcypromineThe metabolism of Labetalol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Labetalol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Labetalol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Labetalol.Approved, Investigational, Nutraceutical
TretoquinolThe risk or severity of adverse effects can be increased when Labetalol is combined with Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Labetalol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Labetalol.Vet Approved
TrichlormethiazideLabetalol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Labetalol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Labetalol.Approved, Vet Approved
TrimazosinLabetalol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Labetalol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Labetalol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Labetalol.Approved
TulobuterolLabetalol may decrease the vasoconstricting activities of Tulobuterol.Investigational
TyramineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tyramine.Investigational, Nutraceutical
UdenafilUdenafil may increase the hypotensive activities of Labetalol.Approved, Investigational
UnoprostoneLabetalol may increase the hypotensive activities of Unoprostone.Approved
UrapidilLabetalol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Labetalol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Labetalol.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Labetalol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Labetalol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Labetalol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Labetalol is combined with Verapamil.Approved
VincamineLabetalol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineLabetalol may increase the hypotensive activities of Vinpocetine.Investigational
XamoterolLabetalol may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideLabetalol may increase the hypotensive activities of Xipamide.Experimental
XylazineLabetalol may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
YM-178Labetalol may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
ZiconotideLabetalol may increase the hypotensive activities of Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Labetalol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Labetalol can be decreased when combined with Ziprasidone.Approved
ZofenoprilLabetalol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Labetalol.Withdrawn
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

U.S. Patent 4,012,444.

General References
Not Available
External Links
Human Metabolome Database
HMDB14736
KEGG Compound
C07063
PubChem Compound
3869
PubChem Substance
46505511
ChemSpider
3734
BindingDB
25758
ChEBI
6343
ChEMBL
CHEMBL429
Therapeutic Targets Database
DAP000038
PharmGKB
PA164743150
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Labetalol
ATC Codes
C07BG01 — Labetalol and thiazidesC07CG01 — Labetalol and other diureticsC07AG01 — Labetalol
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (401 KB)
MSDS
Download (53.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareControlled Hypotension for Nasal Surgeries1
0RecruitingPreventionChronic Hypertension Complicating Pregnancy (Diagnosis) / Preeclampsia1
0RecruitingPreventionObesity, Morbid / Preeclampsia1
0Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
1, 2CompletedTreatmentCraniotomy / Hypertensive1
1, 2WithdrawnTreatmentHypertensive / Pregnancy Toxemias / Proteinuria1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentStroke, Acute1
2CompletedTreatmentTobacco Use Disorders1
2RecruitingTreatmentBloodpressure / Heart Rate1
2RecruitingTreatmentIntracerebral Hemorrhage1
2, 3RecruitingTreatmentSevere Pre-Eclampsia, Antepartum1
2, 3Unknown StatusTreatmentHydralazine Adverse Reaction / Pre-eclampsia Superimposed Pre-existing Hypertension / Pregnancy associated hypertension / Prophylaxis of preeclampsia1
2, 3WithdrawnPreventionChronic Hypertension / Gestational Hypertension / Preeclampsia / Pregnancy associated hypertension / Superimposed Preeclampsia1
3CompletedTreatmentPregnancy associated hypertension1
3Not Yet RecruitingTreatmentPostnatal Hypertension1
4CompletedTreatmentHypertensive Urgency1
4RecruitingPreventionHypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4RecruitingPreventionSurgery, Laparoscopic1
4RecruitingTreatmentHypertension in Pregnancy / Preeclampsia1
4RecruitingTreatmentHypertensive1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentSevere Postpartum Hypertension1
Not AvailableUnknown StatusPreventionIntubation, Endotracheal / Patients Who Are Intubated for General Anesthesia1
Not AvailableWithdrawnTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
  • Apothecon inc div bristol myers squibb
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Taylor pharmaceuticals
  • Sagent strides llc
  • Schering corp sub schering plough corp
  • Prometheus laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous5 mg/mL
InjectionIntravenous5 mg/mL
TabletOral200 mg/1
TabletOral300 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
LiquidIntravenous5 mg
SolutionIntravenous5 mg
TabletOral100 mg
TabletOral100 mg/1
TabletOral200 mg
Prices
Unit descriptionCostUnit
Labetalol Hydrochloride 5 mg/ml1.36USD ml
Trandate 300 mg tablet1.28USD tablet
Trandate 5 mg/ml vial1.25USD ml
Trandate 200 mg tablet1.08USD tablet
Labetalol hcl 300 mg tablet1.02USD tablet
Normodyne 200 mg tablet1.0USD tablet
Labetalol hcl 200 mg tablet0.76USD tablet
Trandate 100 mg tablet0.68USD tablet
Labetalol hcl 100 mg tablet0.53USD tablet
Trandate 200 mg Tablet0.47USD tablet
Trandate 100 mg Tablet0.27USD tablet
Labetalol hcl 5 mg/ml vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)188 °CU.S. Patent 4,012,444.
water solubility117 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.09HANSCH,C ET AL. (1995)
Caco2 permeability-5.03ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00578 mg/mLALOGPS
logP1.73ALOGPS
logP1.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.05ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area95.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity94.72 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier-0.8313
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7073
P-glycoprotein inhibitor INon-inhibitor0.8908
P-glycoprotein inhibitor IINon-inhibitor0.9269
Renal organic cation transporterNon-inhibitor0.8457
CYP450 2C9 substrateNon-substrate0.7448
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6202
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8383
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9189
BiodegradationNot ready biodegradable0.945
Rat acute toxicity2.1174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Non-inhibitor0.7398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-03dl-7900000000-e18d52bcb93357c4a7e2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0319000000-cd3fa186952809ae3558
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0519000000-0a8da4acfa8cd259fb3f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-4928000000-117458013dbd49aaf54b

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Benzamides / Benzoyl derivatives / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Secondary alcohols / Primary carboxylic acid amides / Amino acids and derivatives / 1,2-aminoalcohols / Dialkylamines
show 4 more
Substituents
Salicylamide / Benzamide / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / Vinylogous acid / Amino acid or derivatives / 1,2-aminoalcohol / Secondary alcohol
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
benzamides, secondary amino compound (CHEBI:6343)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Riva E, Mennini T, Latini R: The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol. 1991 Dec;104(4):823-8. [PubMed:1687367]
  2. Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L: Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. Arch Int Pharmacodyn Ther. 1984 Dec;272(2):256-63. [PubMed:6151824]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  4. Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S: [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Apr;77(4):435-45. [PubMed:7286847]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818]
  7. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  8. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Doggrell SA: The effects of labetalol and dilevalol on isolated cardiovascular preparations of the guinea-pig and rat. J Pharm Pharmacol. 1992 Dec;44(12):1001-6. [PubMed:1361547]
  2. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of labetalol, dilevalol, amosulalol and KF-4317 on the rat isolated aorta. J Pharm Pharmacol. 1988 Nov;40(11):812-5. [PubMed:2907566]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  5. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Bernstein JS, Ebert TJ, Stowe DF, Schmeling WT, Nelson MA, Woods MP: Partial attenuation of hemodynamic responses to rapid sequence induction and intubation with labetalol. J Clin Anesth. 1989;1(6):444-51. [PubMed:2696507]
  2. Nakamura T, Maruyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta. Pharmacology. 1999 Nov;59(5):234-8. [PubMed:10529655]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  4. Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers. Curr Hypertens Rep. 2007 Aug;9(4):269-77. [PubMed:17686376]
  5. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34